Diderik Børsting Schnitler

Vorsitzender bei

NLI AS

80 Jahre

11 Beziehungen

Industrial Services

Transportation

Energy Minerals

Profil

Diderik Børsting Schnitler is currently the Chairman of NLI AS, Stabæk Holding AS, Rainpower AS, Sensorlink AS, Stabæk Drift AS, AlgiPharma Holding AS, AlgiPharma APR AS, and President of Næringslivets Hovedorganisasjon.
He previously served as President & CEO of Saga Petroleum ASA and Krüger Kaldnes AS, Executive Vice President of Kværner ASA, and Chairman of Wallenius Wilhelmsen ASA, Zalaris ASA, Valhalla Oil & Gas AS, Det Norske Oljeselskap ASA, and Wilh.
Wilhelmsen Holding ASA. He was also a Director of Wallenius Wilhelmsen Ocean AS.
He graduated from the Norwegian University of Science & Technology in 1970.

Aktive Positionen von Diderik Børsting Schnitler

Unternehmen	Position	Beginn
NLI AS NLI AS Engineering & ConstructionIndustrial Services Provides offshore engineering services	Vorsitzender	29.07.2011
Rainpower AS Rainpower AS Engineering & ConstructionIndustrial Services Operates hydro electric power plants	Vorsitzender	29.07.2011
Stabæk Holding AS	Vorsitzender	29.07.2011
Stabæk Drift AS	Vorsitzender	29.07.2011
AlgiPharma Holding AS AlgiPharma Holding AS AlgiPharma Holding AS is a privately owned, Norwegian clinical-stage biopharmaceutical company that specializes in developing proprietary alginate oligosaccharide technology derived from brown seaweed. The company is based in Sandvika, Norway. The company’s platform produces highly purified, GMP-compliant oligosaccharides with properties such as water solubility, stability, non-toxicity, and biocompatibility. This technology is used as a drug delivery platform and as standalone active pharmaceutical ingredients targeting diseases including cystic fibrosis, COPD, infectious diseases, and wound healing. The oligosaccharides help release stagnant mucus, disrupt microbial biofilms, inhibit microbial adherence and virulence, prevent fungal tissue invasion, and enhance therapeutic delivery and efficacy. The technology can also be conjugated with antimicrobials to reduce toxicity without inducing microbial resistance. AlgiPharma has completed six clinical trials for its lead drug candidate targeting cystic fibrosis and maintains a comprehensive preclinical toxicology portfolio supporting multiple formulations for inhalation, oral, intravenous, and topical administration.	Direktor/Vorstandsmitglied	29.07.2011
AlgiPharma APR AS	Direktor/Vorstandsmitglied	29.07.2011
Næringslivets Hovedorganisasjon Næringslivets Hovedorganisasjon Personnel ServicesCommercial Services Provides emploemnet services	Präsident	-

Alle aktiven Positionen von Diderik Børsting Schnitler

Ehemalige bekannte Positionen von Diderik Børsting Schnitler

Unternehmen	Position	Ende
Sensorlink AS	Vorsitzender	02.12.2024
Det Norske Oljeselskap ASA /Old/ Det Norske Oljeselskap ASA /Old/ Oil & Gas ProductionEnergy Minerals Operates a petroleum company	Vorsitzender	26.06.2009
░░░░ ░░░░░░░░░ ░░░	░░░░░░░░░░░░░░░░░░░░░	░░░░░░░░░░
░░░░░░░░ ░░░	░░░░░░░░░ ░░░░░░░░░░░░░░░░░	░░░░░░░░░░
░░░░░░░ ░░░░░░░ ░░	░░░░░░░░░░░░░░░░░░░░░	░░░░░░░░░░

Sehen Sie sich die Erfahrung von Diderik Børsting Schnitler im Detail an

Ausbildung von Diderik Børsting Schnitler

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Diderik Børsting Schnitler im Detail an

Beziehungen

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Private Unternehmen	18
WALLENIUS WILHELMSEN ASA WALLENIUS WILHELMSEN ASA Marine ShippingTransportation Provides shipping and logistics services & functions as an investment holding company	Transportation
Wallenius Wilhelmsen Ocean AS Wallenius Wilhelmsen Ocean AS Air Freight/CouriersTransportation Provides global factory-to-dealer transport solutions	Transportation
Saga Petroleum ASA Saga Petroleum ASA Oil & Gas ProductionEnergy Minerals Provides oil and gas exploration services	Energy Minerals
Næringslivets Hovedorganisasjon Næringslivets Hovedorganisasjon Personnel ServicesCommercial Services Provides emploemnet services	Commercial Services
Zalaris ASA Zalaris ASA Personnel ServicesCommercial Services Provides human capital management and payroll solutions	Commercial Services
Norwegian University of Science & Technology Norwegian University of Science & Technology Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Valhalla Oil & Gas AS Valhalla Oil & Gas AS Oilfield Services/EquipmentIndustrial Services Indentifies oil and gas opportunities	Industrial Services
Det Norske Oljeselskap ASA /Old/ Det Norske Oljeselskap ASA /Old/ Oil & Gas ProductionEnergy Minerals Operates a petroleum company	Energy Minerals
NLI AS NLI AS Engineering & ConstructionIndustrial Services Provides offshore engineering services	Industrial Services
Stabæk Holding AS
Krüger Kaldnes AS Krüger Kaldnes AS Environmental ServicesIndustrial Services Provides wastewater treatment solutions	Industrial Services
Rainpower AS Rainpower AS Engineering & ConstructionIndustrial Services Operates hydro electric power plants	Industrial Services
Wilh. Wilhelmsen Holding ASA Wilh. Wilhelmsen Holding ASA Other TransportationTransportation Provides maritime services	Transportation
Kværner ASA Kværner ASA Engineering & ConstructionIndustrial Services Provides engineering, procurement and construction services for offshore platforms and onshore plants	Industrial Services
Sensorlink AS
Stabæk Drift AS
AlgiPharma Holding AS AlgiPharma Holding AS AlgiPharma Holding AS is a privately owned, Norwegian clinical-stage biopharmaceutical company that specializes in developing proprietary alginate oligosaccharide technology derived from brown seaweed. The company is based in Sandvika, Norway. The company’s platform produces highly purified, GMP-compliant oligosaccharides with properties such as water solubility, stability, non-toxicity, and biocompatibility. This technology is used as a drug delivery platform and as standalone active pharmaceutical ingredients targeting diseases including cystic fibrosis, COPD, infectious diseases, and wound healing. The oligosaccharides help release stagnant mucus, disrupt microbial biofilms, inhibit microbial adherence and virulence, prevent fungal tissue invasion, and enhance therapeutic delivery and efficacy. The technology can also be conjugated with antimicrobials to reduce toxicity without inducing microbial resistance. AlgiPharma has completed six clinical trials for its lead drug candidate targeting cystic fibrosis and maintains a comprehensive preclinical toxicology portfolio supporting multiple formulations for inhalation, oral, intravenous, and topical administration.
AlgiPharma APR AS